ClinicalTrials.gg
RecruitingNCT05896293Updated Jul 13, 2026

Kisspeptin Administration Subcutaneously to Patients With IHH

A Phase 2 interventional study of kisspeptin 112-121 and leuprolide acetate in Hypogonadotropic Hypogonadism, sponsored by Stephanie B. Seminara, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Stephanie B. Seminara, MD · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2023, registered May 2023).
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Planned enrollment
91st of 154
36 · median 45
Started
2023
with 1 other
Phase 2
54 of 185
4 open now
Primary completion
2028-05
later than 10 of 13 live
Registered
174th of 185
by date
Lead sponsor
6 of 185
Stephanie B. Seminara, MD

Among the 185 studies in Hypogonadism with a site in United States, this one is the 91st largest by planned enrollment of the 154 interventional ones that give a count, is one of 2 that started in 2023, is one of 54 in phase 2, reaches primary completion later than 10 of the 13 other live ones, and was the 174th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time.

Funding Source: FDA OOPD

Read the detailed description

Assignment: All study subjects will undergo the same interventions.

Delivery of Interventions:

  • Each subject will undergo a review of their medical history, physical exam, and screening laboratories.
  • A single SC injection of leuprolide acetate may be administered approximately six days before kisspeptin administration. (Previously administration of Gonadotropin Releasing Hormone (GnRH) was used in this study.)
  • A pelvic ultrasound will be performed on women to assess baseline follicular size.
  • A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
  • During the course of kisspeptin administration, subjects will
  • Undergo q10 min blood sampling (approximately 10 sessions, 70 minutes each)
  • For women, undergo pelvic ultrasounds (approximately 4 sessions)
  • Optional q10 min sampling up to 8 hours may take place before and after the course of kisspeptin
03

Conditions studied

  • Hypogonadotropic Hypogonadism

Browse trials for

Keywords

  • Hypogonadotropic Hypogonadism
  • Kisspeptin
  • Idiopathic Hypogonadotropic Hypogonadism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Congenital IHH
  • Confirmed diagnosis by medical provider supported by low sex in the setting of low or inappropriately normal gonadotropins
  • Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg)
  • No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate for that particular medication and method of administration
  • If applicable, willing to use methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
  • Excessive alcohol consumption (>10 drinks/week)
  • Active use of illicit drugs (not including marijuana)
  • For women:
  • Pregnant or trying to become pregnant
  • Breast feeding
  • History of: bilateral oophorectomy (both ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    kisspeptin pump

    SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes); administration of a single shot of leuprolide acetate (previously GnRH was used in this study)

    Drug: kisspeptin 112-121 · Drug: leuprolide acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Average change in luteinizing hormone (LH) pulse amplitude

    Average difference in LH amplitude after the first dose of kisspeptin (day 1) compared to the last dose of kisspeptin (day 15)

    Time frame: 2 weeks

Secondary outcomes

  1. Percentage of female participants who demonstrate achievement of a mature follicle or show evidence of ovulation

    Percentage of female participants that develop a mature follicle or ovulate. Mature follicle achievement is defined as evidence of a follicle with maximum diameter ≥18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for May 2028, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
Feb 3, 2023
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05896293
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Jun 9, 2023
Start date
Feb 3, 2023
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Study Coordinator
Contact
MGHKisspeptinResearch@partners.org
617-726-1895
Stephanie Seminara, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KISS1 protein, human · Leuprolide

Start the discussion